Evommune (EVMN) Return on Sales (2025 - 2026)
Evommune (EVMN) posted quarterly Return on Sales of 0.14% for Q1 2026, down 9.0% year-over-year from 0.15% in Q1 2025, and down 112.0% quarter-over-quarter from 0.06% in Q4 2025.
Evommune (EVMN) Return on Sales (2025 - 2026) Analysis & Trends
Evommune (EVMN) has reported Return on Sales for 2 consecutive years, with 0.14% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Sales fell 9.0% year-over-year to 0.14%; the TTM figure through Mar 2026 stood at 0.14% (changed N/A YoY), while the FY2025 annual figure was 0.1%, down 1.0% from the prior year.
- Return on Sales fell to 0.14% in Q1 2026 per EVMN's latest filing, from 0.06% in the prior quarter.
- Across five years, Return on Sales topped out at 0.02% in Q3 2025 and bottomed at 0.14% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | -0.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.23% |
| Mar 31, 2026 | -0.14% |
| Dec 31, 2025 | -0.06% |
| Sep 30, 2025 | -0.02% |
| Mar 31, 2025 | -0.05% |